切换至 "中华医学电子期刊资源库"
高级检索
中华医学超声杂志（电子版）

中华医学超声杂志（电子版） ›› 2023, Vol. 20 ›› Issue (06) : 631 -635. doi: 10.3877/cma.j.issn.1672-6448.2023.06.010

浅表器官超声影像学

超声联合乳腺X线摄影及PR、Her-2预测高级别与中低级别乳腺导管原位癌的价值
武壮壮, 张晓娟, 史泽洪, 史瑶, 原韶玲†()   
  1. 030001　太原，山西医科大学；030013　太原，山西医科大学附属山西省肿瘤医院超声科
    030013　太原，山西医科大学附属山西省肿瘤医院放射科
    030032　太原，山西白求恩医院
    030013　太原，山西医科大学附属山西省肿瘤医院超声科
  • 收稿日期:2021-12-15 出版日期:2023-06-01
  • 通信作者: 原韶玲

Prognostic value of ultrasound combined with mammography and PR and HER-2 status in high-grade and middle-low-grade ductal carcinoma in situ of the breast

Zhuangzhuang Wu, Xiaojuan Zhang, Zehong Shi, yao Shi, Shaoling Yuan†()   

  1. Shanxi Medical University, Taiyuan 030001,China; Department of Ultrasound, Affiliated Tumor Hospital of Shanxi Medical University, Taiyuan 030013, China
    Department of Radiology, Affiliated Tumor Hospital of Shanxi Medical University, Taiyuan 030013, China
    Shanxi Bethune Hospital, Taiyuan 030032, China
    Department of Ultrasound, Affiliated Tumor Hospital of Shanxi Medical University, Taiyuan 030013, China
  • Received:2021-12-15 Published:2023-06-01
  • Corresponding author: Shaoling Yuan
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

武壮壮, 张晓娟, 史泽洪, 史瑶, 原韶玲. 超声联合乳腺X线摄影及PR、Her-2预测高级别与中低级别乳腺导管原位癌的价值[J]. 中华医学超声杂志（电子版）, 2023, 20(06): 631-635.

Zhuangzhuang Wu, Xiaojuan Zhang, Zehong Shi, yao Shi, Shaoling Yuan. Prognostic value of ultrasound combined with mammography and PR and HER-2 status in high-grade and middle-low-grade ductal carcinoma in situ of the breast[J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(06): 631-635.

目的

探讨超声、乳腺X线影像学特征及孕激素受体（PR）、人表皮生长因子-2（Her-2）对高级别与中低级别乳腺导管原位癌（DCIS）的预测价值。

方法

回顾性分析山西省肿瘤医院2015年1月至2020年12月经手术病理证实的196例DCIS患者，术前均行超声及乳腺X线检查且病理资料完整。根据术后病理结果将其分为高级别DCIS组80例和中低级别DCIS组116例。应用单因素分析方法比较2组患者影像表现及免疫组化的差异，将差异有统计学意义的因素纳入多因素Logistic回归分析，分析高级别与中低级别DCIS的独立预测因素。

结果

将单因素分析有统计学意义的超声表现为肿块、乳腺X线为微钙化、雌激素受体（ER）、PR及Her-2纳入二元 Logistic 回归进行多因素分析。结果表明，超声表现为肿块（OR=0.248，95％CI：0.109~0.562）、PR受体阳性（OR=0.230，95％CI：0.057~0.931）是中低级别DCIS的独立预测因素。乳腺X线表现为微钙化（OR=4.048，95％CI：1.736~9.440）、Her-2阳性（OR=6.160，95％CI：2.149~17.655）是高级别DCIS的独立预测因素。

结论

术前影像学检查及免疫组化PR、Her-2测定对DCIS的预测及DCIS患者的管理及治疗具有一定临床价值。

关键词: 乳腺导管原位癌, 超声检查, 乳腺X线摄影, 免疫组织化学
Objective

To assess the predictive value of ultrasonography, mammography, and progesterone receptor (PR) and human epidermal growth factor 2 (HER-2) status for high-grade and middle-low-grade ductal carcinoma in situ (DCIS) of the breast.

Methods

A retrospective analysis was performed on 196 patients with breast DCIS confirmed by surgical pathology from January 2015 to December 2020 at Shanxi Tumor Hospital. All patients were examined by ultrasonography and mammography before operation, and had complete pathological data. According to postoperative pathological results, the patients were divided into a high-grade DCIS group (n=80) and a middle-low-grade DCIS group (n=116). Univariate analysis was used to compare the differences in imaging and immunohistochemical features of patients in the two groups. Factors with statistically significant differences in the univariate analysis were included in multivariate Logistic regression analysis to analyze the independent predictors of high-grade and middle-low-grade DCIS.

Results

The statistically significant parameters identified in the univariate analysis, such as mass on ultrasound, microcalcification on mammography, and estrogen receptor (ER), PR, and HER-2 status, were included in binary logistic regression for multivariate analysis. The results showed that mass (odds ratio [OR]=0.248, 95% confidence interval [CI]:0.109～0.562) and PR positivity (OR=0.230, 95%CI:0.057~0.931) were independent predictor of middle-low-grade DCIS. Microcalcification (OR=4.048,95%CI:1.736~9.440) and HER-2 positivity (OR=6.160, 95%CI:2.149~17.655) were identified to be independent predictor of high-grade DCIS.

Conclusions

Preoperative imaging examination and immunohistochemical determination of PR and HER-2 status have appreciated clinical value for the prediction of DCIS and the management and treatment of DCIS patients.

Key words: Ductal carcinoma?in?situ of the breast, Ultrasonography, Mammography, Immunohistochemistry
表1 高级别与中低级别DCIS组单因素比较分析［例（%）］
因素 高级别组（n=80） 中低级别组（n=116） 统计值 P值
年龄（岁，
x¯
±s）		 51.33±9.679 51.43±11.660 t'=-0.069 0.945
临床表现 χ2=0.012 0.914
肿块 66（82.5） 95（81.9）
其他 14（17.5） 21（18.1）
ER χ2=47.569 ＜0.001
阳性 40（50.0） 108（93.1）
阴性 40（50.0） 8（6.9）
PR χ2=59.440 ＜0.001
阳性 29（36.3） 103（88.8）
阴性 51（63.7） 13（11.2）
Her-2 χ2=51.380 ＜0.001
阳性 43（53.8） 9（7.8）
阴性 37（46.3） 107（92.2）
超声表现 χ2=31.826 ＜0.001
肿块型 21（26.3） 78（67.2）
非肿块型 59（73.8） 38（32.8）
X线表现 χ2=23.818 ＜0.001
微钙化 60（75.0） 46（39.7）
无微钙化 20（25.0） 70（60.3）
图2 患者，女性，57岁，右乳高级别乳腺导管原位癌乳腺X线图像示多发微钙化
表2 高级别与中低级别DCIS预测因素赋值表
因素 变量名 变量赋值说明
ER X1 阳性=1，阴性=0
PR X2 阳性=1，阴性=0
Her-2 X3 阳性=1，阴性=0
肿块型 X4 肿块型=1，非肿块型=0
微钙化 X5 有微钙化=1，无微钙化=0
病理结果 Y 高级别=1，中低级别=0
表3 高级别与中低级别DCIS多因素Logistic回归分析
因素 β值 SE值 Waldχ2 P值 OR值 95%CI
ER -0.488 0.818 0.356 0.551 0.614 0.123~3.053
PR -1.468 0.713 4.427 0.039 0.230 0.057~0.931
Her-2 1.818 0.537 11.451 0.001 6.160 2.149~17.655
肿块型 -1.395 0.418 11.154 0.001 0.248 0.109~0.562
微钙化 1.398 0.432 10.473 0.001 4.048 1.736~9.440
常量 0.319 0.653 0.239 0.625 1.376
[1]
Sanati S. Morphologic and molecular features of breast ductal carcinoma in situ [J]. Am J Pathol, 2019, 189(5): 946-955.
[2]
Liu Y, West R, Weber J, et al. Race and risk of subsequent aggressive breast cancer following ductal carcinoma in situ [J]. Cancer, 2019, 125(18): 3225-3233.
[3]
Ponti A, Ronco G, Lynge E, et al. Low-grade screen-detected ductal carcinoma in situ progresses more slowly than high-grade lesions: evidence from an international multi-centre study [J]. Breast Cancer Res Treat, 2019, 177(3): 761-765.
[4]
孙强, 徐兵河, 邵志敏. 乳腺原位癌诊疗专家共识 [J]. 中华肿瘤杂志, 2016, 38(12): 942-947.
[5]
Tse G, Tan P, Cheung H, et al. Intermediate to highly suspicious calcification in breast lesions: a radio-pathologic correlation [J]. Breast Cancer Res Treat, 2008, 110(1): 1-7.
[6]
O'Flynn E, Morel J, Gonzalez J, et al. Prediction of the presence of invasive disease from the measurement of extent of malignant microcalcification on mammography and ductal carcinoma in situ grade at core biopsy [J]. Clin Radiol, 2009, 64(2): 178-183.
[7]
Cha H, Chang Y, Lee E, et al. Ultrasonographic features of pure ductal carcinoma in situ of the breast: correlations with pathologic features and biological markers [J]. Ultrasonography (Seoul, Korea), 2018, 37(4): 307-314.
[8]
包凌云. 乳腺导管原位癌的超声诊断 [J]. 浙江医学, 2019, 41(11): 1109-1112,1238.
[9]
刘慧敏, 曹小丽, 刘瑞华. 乳腺导管原位癌超声表现与病理关系的研究 [J]. 中华实验外科杂志, 2017, 34(4): 581-583.
[10]
Choi SH, Choi JS, Han BK, et al. Long-term Surveillance of Ductal Carcinoma in Situ Detected with Screening Mammography versus US: Factors Associated with Second Breast Cancer [J]. Radiology, 2019, 292(1): 37-48.
[11]
Bragg A, Candelaria R, Adrada B, et al. Imaging of noncalcified ductal carcinoma in situ [J]. J Clin Imaging Sci, 2021, 11: 34.
[12]
van Dooijeweert C, van Diest P, Baas I, et al. Grading variation in 2,934 patients with ductal carcinoma in situ of the breast: the effect of laboratory-and pathologist-specific feedback reports [J]. Diagn Pathol, 2020, 15(1): 52.
[13]
Gunawardena D, Burrows S, Taylor D. Non-mass versus mass-like ultrasound patterns in ductal carcinoma in situ: is there an association with high-risk histology? [J]. Clin Radiol, 2020, 75(2): 140-147.
[14]
Watanabe T, Yamaguchi T, Tsunoda H, et al. Ultrasound image classification of ductal carcinoma in situ (DCIS) of the breast: analysis of 705 DCIS lesions [J].Ultrasound Med Biol, 2017, 43(5): 918-925.
[15]
Park J, Park Y, Kim E, et al. Sonographic findings of high-grade and non-high-grade ductal carcinoma in situ of the breast [J]. J Ultrasound Med, 2010, 29(12): 1687-1697.
[16]
中国抗癌协会乳腺癌诊治指南与规范(2019年版) [J]. 中国癌症杂志, 2019, 29(8): 609-680.
[17]
Shehata M, Grimm L, Ballantyne N, et al. Ductal carcinoma in situ: current concepts in biology, imaging, and treatment [J]. J Breast Imaging, 2019, 1(3): 166-176.
[18]
Coleman W. Breast ductal carcinoma in situ: precursor to invasive breast cancer [J]. Am J Pathol, 2019, 189(5): 942-945.
[19]
Kong J, Liu X, Zhang X, et al. The predictive value of calcification for the grading of ductal carcinoma in situ in Chinese patients [J]. Medicine, 2020, 99(28): e20847.
[20]
Wu L, Zhao Y, Lin P, et al. Preoperative ultrasound radiomics analysis for expression of multiple molecular biomarkers in mass type of breast ductal carcinoma in situ [J]. BMC Med Imaging, 2021, 21(1): 84.
[21]
Kim HR, Jung HK. Histopathology findings of non-mass cancers on breast ultrasound [J]. Acta Radiol Open, 2018, 7(6): 2058460118774957.
[1] 魏淑婕, 惠品晶, 丁亚芳, 张白, 颜燕红, 周鹏, 黄亚波. 单侧颈内动脉闭塞患者行颞浅动脉-大脑中动脉搭桥术的脑血流动力学评估[J]. 中华医学超声杂志（电子版）, 2023, 20(10): 1046-1055.
[2] 张璇, 马宇童, 苗玉倩, 张云, 吴士文, 党晓楚, 陈颖颖, 钟兆明, 王雪娟, 胡淼, 孙岩峰, 马秀珠, 吕发勤, 寇海燕. 超声对Duchenne肌营养不良儿童膈肌功能的评价[J]. 中华医学超声杂志（电子版）, 2023, 20(10): 1068-1073.
[3] 朱连华, 费翔, 韩鹏, 姜波, 李楠, 罗渝昆. 高帧频超声造影在胆囊息肉样病变中的鉴别诊断价值[J]. 中华医学超声杂志（电子版）, 2023, 20(09): 904-910.
[4] 张梅芳, 谭莹, 朱巧珍, 温昕, 袁鹰, 秦越, 郭洪波, 侯伶秀, 黄文兰, 彭桂艳, 李胜利. 早孕期胎儿头臀长正中矢状切面超声图像的人工智能质控研究[J]. 中华医学超声杂志（电子版）, 2023, 20(09): 945-950.
[5] 陈舜, 薛恩生, 叶琴. PDCA在持续改进超声危急值管理制度中的价值[J]. 中华医学超声杂志（电子版）, 2023, 20(09): 974-978.
[6] 周钰菡, 肖欢, 唐毅, 杨春江, 周娟, 朱丽容, 徐娟, 牟芳婷. 超声对儿童髋关节暂时性滑膜炎的诊断价值[J]. 中华医学超声杂志（电子版）, 2023, 20(08): 795-800.
[7] 刘欢颜, 华扬, 贾凌云, 赵新宇, 刘蓓蓓. 颈内动脉闭塞病变管腔结构和血流动力学特征分析[J]. 中华医学超声杂志（电子版）, 2023, 20(08): 809-815.
[8] 郏亚平, 曾书娥. 含鳞状细胞癌成分的乳腺化生性癌的超声与病理特征分析[J]. 中华医学超声杂志（电子版）, 2023, 20(08): 844-848.
[9] 张丽丽, 陈莉, 余美琴, 聂小艳, 王婧玲, 刘婷. PDCA循环法在超声浅表器官亚专科建设中的应用[J]. 中华医学超声杂志（电子版）, 2023, 20(07): 717-721.
[10] 罗刚, 泮思林, 陈涛涛, 许茜, 纪志娴, 王思宝, 孙玲玉. 超声心动图在胎儿心脏介入治疗室间隔完整的肺动脉闭锁中的应用[J]. 中华医学超声杂志（电子版）, 2023, 20(06): 605-609.
[11] 黄佳, 石华, 张玉国, 胡佳琪, 陈茜. 胎儿左头臂静脉正常与异常超声图像特征及其临床意义[J]. 中华医学超声杂志（电子版）, 2023, 20(06): 610-617.
[12] 袁泽, 庄丽. 超声检测胎儿脐动脉和大脑中动脉血流对胎儿宫内窘迫的诊断价值[J]. 中华医学超声杂志（电子版）, 2023, 20(06): 618-621.
[13] 廖梅, 张红君, 金洁玚, 吕艳, 任杰. 床旁超声造影对肝移植术后早期肝动脉血栓的诊断价值[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 630-634.
[14] 杨天池, 韩威, 邱枫, 祁佳慧. 术中胰腺超声弹性成像在胰腺质地评估中的应用[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 646-650.
[15] 岳瑞雪, 孔令欣, 郝鑫, 杨进强, 韩猛, 崔国忠, 王建军, 张志生, 孔凡庭, 张维, 何文博, 李现桥, 周新平, 徐东宏, 胡崇珠. 乳腺癌HER2蛋白表达水平预测新辅助治疗疗效的真实世界研究[J]. 中华临床医师杂志(电子版), 2023, 17(07): 765-770.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号